Core One Labs Inc
CNSX:COOL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Core One Labs Inc
Stock-Based Compensation
Core One Labs Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Core One Labs Inc
CNSX:COOL
|
Stock-Based Compensation
CA$271.7k
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Stock-Based Compensation
$216m
|
CAGR 3-Years
20%
|
CAGR 5-Years
16%
|
CAGR 10-Years
4%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Stock-Based Compensation
CA$2.8m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
3%
|
|
|
Cronos Group Inc
TSX:CRON
|
Stock-Based Compensation
$7.1m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Stock-Based Compensation
$17.9m
|
CAGR 3-Years
2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Stock-Based Compensation
CA$8.1m
|
CAGR 3-Years
63%
|
CAGR 5-Years
33%
|
CAGR 10-Years
6%
|
|
Core One Labs Inc
Glance View
Core One Labs, Inc. is a biotechnology company, which engages in the manufacture of cannabis-infused strips. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2011-08-17. The firm is focused on advancing psychedelic medicines to market through delivery systems and psychedelic assisted psychotherapy and active pharmaceutical ingredients (API) grade psilocybin manufacturing. Core One has developed its technology, thin film oral strip, which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining bioavailability. The firm also intends to develop and apply the technology to psychedelic compounds, such as psilocybin. Core One produce current Good Manufacturing Practice (cGMP) API grade psilocybin for use by pharmaceutical companies, API manufacturers and organizations conducting clinical trials, providing access to organizations. Core One also holds an interest in medical clinics, which maintain a combined database of approximately 275,000 patients.
See Also
What is Core One Labs Inc's Stock-Based Compensation?
Stock-Based Compensation
271.7k
CAD
Based on the financial report for Dec 31, 2023, Core One Labs Inc's Stock-Based Compensation amounts to 271.7k CAD.
What is Core One Labs Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
-34%
The average annual Stock-Based Compensation growth rates for Core One Labs Inc have been -50% over the past three years , -34% over the past five years .